Eli Lilly ( LLY +0.87%) delivered a gain worthy of a technology growth stock last year. The pharma giant's shares soared 39%, ...

The choice isn't that hard.

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" ...

By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Why economic leverage beats military pressure on Greenland, and how Denmark’s exposure through Novo Nordisk makes trade tools ...

By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U.S. in the first ...

Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging ...

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...